AC
CVKD icon

Armistice Capital’s Cadrenal Therapeutics CVKD Stock Holding History

Armistice Capital’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-89,972
Closed -$823K – 289
2024
Q1 		$823K Buy
89,972
+62,353
+226% +$791K 0.01% 173
2023
Q4 		$307K Sell
27,619
-37,867
-58% -$300K ﹤0.01% 218
2023
Q3 		$668K Buy
+65,486
New +$931K 0.01% 158

Other funds holding CVKD

APP
Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFO
Biltmore Family Office Charlotte, North Carolina $716M AUM 21.09% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's CVKD Position: Q2 2024 in Review

Armistice Capital sold out of Cadrenal Therapeutics (CVKD) in Q2 2024, closing a stake of 89,972 shares — an estimated $823K sold.

Armistice Capital first reported a position in CVKD in Q3 2023 and held it in 3 quarters. The position peaked at $823K in Q1 2024. 9 funds tracked by Wall St. Rank hold CVKD as of Q2 2024.

  • Armistice Capital reported no remaining Cadrenal Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Armistice Capital sold 89,972 Cadrenal Therapeutics shares in Q2 2024, an estimated $823K.
  • Armistice Capital first reported a position in Cadrenal Therapeutics in Q3 2023 and held it in 3 quarters.
  • Armistice Capital's Cadrenal Therapeutics position peaked at $823K in Q1 2024.
  • 9 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2024.

Based on Armistice Capital's 13F filing for Q2 2024, filed 14 Aug 2024.